Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Evan Leaf, M.D.

Co-Author

This page shows the publications co-authored by David Leaf and Shruti Gupta.
Connection Strength

5.642
  1. Tocilizumab in COVID-19: some clarity amid controversy. Lancet. 2021 05 01; 397(10285):1599-1601.
    View in: PubMed
    Score: 0.970
  2. Diphenhydramine for the prevention of cisplatin-associated acute kidney injury. Kidney Int. 2021 04; 99(4):1025-1026.
    View in: PubMed
    Score: 0.964
  3. Machine Learning Prediction of Death in Critically Ill Patients With Coronavirus Disease 2019. Crit Care Explor. 2021 Aug; 3(8):e0515.
    View in: PubMed
    Score: 0.247
  4. Tissue Plasminogen Activator in Critically Ill Adults with COVID-19. Ann Am Thorac Soc. 2021 Apr 19.
    View in: PubMed
    Score: 0.242
  5. Response to "Is the outcome of SARS-CoV-2 infection in solid organ transplant recipients really similar to that of the general population?" Am J Transplant. 2021 04; 21(4):1672-1673.
    View in: PubMed
    Score: 0.237
  6. Outcomes of Critically Ill Pregnant Women with COVID-19 in the United States. Am J Respir Crit Care Med. 2021 01 01; 203(1):122-125.
    View in: PubMed
    Score: 0.237
  7. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Intern Med. 2021 01 01; 181(1):41-51.
    View in: PubMed
    Score: 0.237
  8. Tocilizumab in Covid-19. N Engl J Med. 2021 01 07; 384(1):86-87.
    View in: PubMed
    Score: 0.236
  9. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med. 2020 11 01; 180(11):1436-1447.
    View in: PubMed
    Score: 0.234
  10. AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. J Am Soc Nephrol. 2021 01; 32(1):161-176.
    View in: PubMed
    Score: 0.233
  11. ABO phenotype and death in critically ill patients with COVID-19. Br J Haematol. 2020 08; 190(4):e204-e208.
    View in: PubMed
    Score: 0.230
  12. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. Am J Kidney Dis. 2020 07; 76(1):63-71.
    View in: PubMed
    Score: 0.222
  13. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol. 2020 02; 31(2):435-446.
    View in: PubMed
    Score: 0.221
  14. Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. Eur J Cancer. 2021 Sep 02; 157:50-58.
    View in: PubMed
    Score: 0.062
  15. Obesity, inflammatory and thrombotic markers, and major clinical outcomes in critically ill patients with COVID-19 in the US. Obesity (Silver Spring). 2021 10; 29(10):1719-1730.
    View in: PubMed
    Score: 0.062
  16. Performance of crisis standards of care guidelines in a cohort of critically ill COVID-19 patients in the United States. Cell Rep Med. 2021 Sep 21; 2(9):100376.
    View in: PubMed
    Score: 0.062
  17. Prone Positioning and Survival in Mechanically Ventilated Patients With Coronavirus Disease 2019-Related Respiratory Failure. Crit Care Med. 2021 07 01; 49(7):1026-1037.
    View in: PubMed
    Score: 0.061
  18. Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors. Am J Kidney Dis. 2021 Jun 24.
    View in: PubMed
    Score: 0.061
  19. Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19. Chest. 2021 09; 160(3):929-943.
    View in: PubMed
    Score: 0.061
  20. d-dimer and Death in Critically Ill Patients With Coronavirus Disease 2019. Crit Care Med. 2021 05 01; 49(5):e500-e511.
    View in: PubMed
    Score: 0.061
  21. Hospital-Level Variation in Death for Critically Ill Patients with COVID-19. Am J Respir Crit Care Med. 2021 04 23.
    View in: PubMed
    Score: 0.061
  22. Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. Intensive Care Med. 2021 02; 47(2):208-221.
    View in: PubMed
    Score: 0.060
  23. Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19. Ann Intern Med. 2021 05; 174(5):622-632.
    View in: PubMed
    Score: 0.060
  24. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021 07; 100(1):196-205.
    View in: PubMed
    Score: 0.059
  25. Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel. Am J Kidney Dis. 2021 06; 77(6):990-992.
    View in: PubMed
    Score: 0.058
  26. Histopathologic Correlates of Kidney Function: Insights From Nephrectomy Specimens. Am J Kidney Dis. 2021 03; 77(3):336-345.
    View in: PubMed
    Score: 0.058
  27. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ. 2020 09 30; 371:m3513.
    View in: PubMed
    Score: 0.058
  28. Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States. Am J Kidney Dis. 2021 02; 77(2):190-203.e1.
    View in: PubMed
    Score: 0.058
  29. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. Am J Transplant. 2020 11; 20(11):3061-3071.
    View in: PubMed
    Score: 0.058
  30. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020 07 23; 136(4):489-500.
    View in: PubMed
    Score: 0.057
  31. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. Kidney Int Rep. 2020 Oct; 5(10):1700-1705.
    View in: PubMed
    Score: 0.057
  32. Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2021 Apr; 161(4):1510-1518.
    View in: PubMed
    Score: 0.057
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.